| Dr Shane Jacob Kibbe, MD | |
|
935 Chambers Blvd, Bardstown, KY 40004 | |
| (502) 834-5676 | |
| Not Available |
| Full Name | Dr Shane Jacob Kibbe |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 12 Years |
| Location | 935 Chambers Blvd, Bardstown, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265708168 | NPI | - | NPPES |
| 01080524A | Other | IN | LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Flaget Memorial Hospital | Bardstown, KY | Hospital |
| Spring View Hospital | Lebanon, KY | Hospital |
| Entity Name | Spring View Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033459854 PECOS PAC ID: 3476557000 Enrollment ID: O20060913000014 |
News Archive
The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.
Functional near-infrared spectroscopy (fNIRS), an optical imaging tool for monitoring of regional blood flow and tissue oxygenation, is being explored as a way to track the brain's response to acute pain in adults and infants.
The United States Senate, in a historic Christmas Eve vote, passed the Patient Protection and Affordable Care Act of 2009 (H.R. 3590). The Women's Health Office Act (WHOA), SWHR's signature piece of legislation, was included as a provision in the health reform bill, marking a tremendous accomplishment for women's health and women's health research and an advancement of SWHR's advocacy work.
Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.
In ongoing support of prostate cancer research, Sanford Siegel, M.D., President and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with a check for $114,248 in support of its prostate cancer research efforts.
› Verified 1 days ago
| Entity Name | Kibbe Orthopedics Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073252375 PECOS PAC ID: 3375925670 Enrollment ID: O20220803001831 |
News Archive
The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.
Functional near-infrared spectroscopy (fNIRS), an optical imaging tool for monitoring of regional blood flow and tissue oxygenation, is being explored as a way to track the brain's response to acute pain in adults and infants.
The United States Senate, in a historic Christmas Eve vote, passed the Patient Protection and Affordable Care Act of 2009 (H.R. 3590). The Women's Health Office Act (WHOA), SWHR's signature piece of legislation, was included as a provision in the health reform bill, marking a tremendous accomplishment for women's health and women's health research and an advancement of SWHR's advocacy work.
Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.
In ongoing support of prostate cancer research, Sanford Siegel, M.D., President and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with a check for $114,248 in support of its prostate cancer research efforts.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shane Jacob Kibbe, MD Po Box 33149, Belfast, ME 04915-0609 Ph: (888) 488-8289 | Dr Shane Jacob Kibbe, MD 935 Chambers Blvd, Bardstown, KY 40004 Ph: (502) 834-5676 |
News Archive
The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.
Functional near-infrared spectroscopy (fNIRS), an optical imaging tool for monitoring of regional blood flow and tissue oxygenation, is being explored as a way to track the brain's response to acute pain in adults and infants.
The United States Senate, in a historic Christmas Eve vote, passed the Patient Protection and Affordable Care Act of 2009 (H.R. 3590). The Women's Health Office Act (WHOA), SWHR's signature piece of legislation, was included as a provision in the health reform bill, marking a tremendous accomplishment for women's health and women's health research and an advancement of SWHR's advocacy work.
Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.
In ongoing support of prostate cancer research, Sanford Siegel, M.D., President and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with a check for $114,248 in support of its prostate cancer research efforts.
› Verified 1 days ago
Jeeshan Ali Faridi, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 875 Pennsylvania Ave, Bardstown, KY 40004 Phone: 502-348-5685 Fax: 502-348-1771 | |
Mark C Duber, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 875 Pennsylvania Ave, Bardstown, KY 40004 Phone: 023-485-6855 | |
Dr. Michael Thomas Sewell, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 875 Pennsylvania Ave, Bardstown, KY 40004 Phone: 502-348-5685 |